AzTrials
AzTrials

Osteogenesis ImperfectaMOVE-OINCT04119388

Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta

A study testing Adapted sports practices in people with Osteogenesis Imperfecta, run by Hospices Civils de Lyon at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functionals limitations and no adapted physicals activity(APA). Read more about this study

Who is it for?
Ages 6 to 17 years
Conditions the study is for
Osteogenesis Imperfecta
What is being tested?
Adapted sports practices
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteFrance
Study dates
4 Nov 2019to 14 Oct 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Child with osteogenesis imperfecta
  • Child followed in the Reference centre for constitutional bone diseases in the Hôpital Femme Mère Enfant
  • Parent (s) / legal guardian who has been informed of the study and has accepted participation in the study by signing the consent.
  • Patient benefiting from a social security scheme

Who cannot join

  • Medical and surgical contraindications to adapted physical activity.

Trial locations and contacts

1 site in 1 country.

France1 site
  • Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant

    Bron, 69500

Other trials in France

About this study

Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functionals limitations and no adapted physicals activity(APA). The hypothesis is that an Adapted physique activity could improve access of activity for patients with Osteogenesis Imperfecta (OI).

The aim of the study is to evaluate benefice of APA,improve aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.

Children with OI between 6 and 18 years old will have a program of supervised "adapted training program" during one year. The program is adapted at each individual and without risk for the patient.

Being tested
Adapted sports practices
Keywords
osteogenesis imperfecta, Adapted sport, Quality of life
Medical subject headings
Osteogenesis Imperfecta

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Adapted sports practicesOther

    Adapted sports practices for 30 minutes twice a week

Study groups in NCT04119388
Study groupRoleWhat they receive
Adapted sports practiceExperimentalpatients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.
Receives: Other: Adapted sports practices

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 6 minutes walk test

    Distance traveled (in meters) in 6 minutes

    Measured: Month 0

  2. 6 minutes walk test

    Distance traveled (in meters) in 6 minutes

    Measured: Month 6

  3. 6 minutes walk test

    Distance traveled (in meters) in 6 minutes

    Measured: Month 12

Secondary outcomes (51)
  1. Weight

    weight in kilograms will be measured with a scale

    Measured: Month 0

  2. Weight

    weight in kilograms will be measured with a scale

    Measured: Month 6

  3. Weight

    weight in kilograms will be measured with a scale

    Measured: Month 12

  4. Height

    Size in meter measured with a meter

    Measured: Month 0

  5. Height

    Size in meter measured with a meter

    Measured: Month 6

  6. Height

    Size in meter measured with a meter

    Measured: Month 12

  7. body mass index

    calculated with weight and height

    Measured: Month 0

  8. body mass index

    calculated with weight and height

    Measured: Month 6

  9. body mass index

    calculated with weight and height

    Measured: Month 12

  10. blood pressure

    measurement of blood pressure (cm Hg)

    Measured: Month 0

  11. blood pressure

    measurement of blood pressure (cm Hg)

    Measured: Month 6

  12. blood pressure

    measurement of blood pressure (cm Hg)

    Measured: Month 12

  13. phosphocalcic biologic parameters

    Ionosodium (mmol/L)

    Measured: Month 0 and Month 12

  14. phosphocalcic biologic parameters

    potassium (mmol/L)

    Measured: Month 0 and Month 12

  15. phosphocalcic biologic parameters

    calcium (mmol/L)

    Measured: Month 0 and Month 12

  16. phosphocalcic biologic parameters

    chlore (mmol/L)

    Measured: Month 0 and Month 12

  17. phosphocalcic biologic parameters

    bicarbonates (mmol/L)

    Measured: Month 0 and Month 12

  18. phosphocalcic biologic parameters

    glucose (mmol/L)

    Measured: Month 0 and Month 12

  19. phosphocalcic biologic parameters

    urea (mmol/L)

    Measured: Month 0 and Month 12

  20. phosphocalcic biologic parameters

    creatinemia (mmol/L)

    Measured: Month 0 and Month 12

  21. phosphocalcic biologic parameters

    phosphorus (mmol/L)

    Measured: Month 0 and Month 12

  22. phosphocalcic biologic parameters

    proteinemia (g/L)

    Measured: Month 0 and Month 12

  23. phosphocalcic biologic parameters

    Vitamin D (nmol/L)

    Measured: Month 0 and Month 12

  24. phosphocalcic biologic parameters

    1-25 OH vitamin D (pmol/L)

    Measured: Month 0 and Month 12

  25. phosphocalcic biologic parameters

    PTH (ng/L)

    Measured: Month 0 and Month 12

  26. phosphocalcic biologic parameters

    alkaline bone phosphatases (U/L)

    Measured: Month 0 and Month 12

  27. phosphocalcic biologic parameters

    CTX (pg/ml)crosslaps

    Measured: Month 0 and Month 12

  28. phosphocalcic biologic parameters

    osteocalcin (µg/L)

    Measured: Month 0 and Month 12

  29. phosphocalcic biologic parameters

    ferritin (µg/L)

    Measured: Month 0 and Month 12

  30. phosphocalcic biologic parameters

    blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L)

    Measured: Month 0 and Month 12

  31. phosphocalcic biologic parameters

    calciuria (mmol/L)

    Measured: Month 0 and Month 12

  32. phosphocalcic biologic parameters

    Ionosodium (mmol/L) potassium (mmol/L), calcium (mmol/L), chlore (mmol/L), bicarbonates (mmol/L), glucose (mmol/L), urea (mmol/L), creatinemia (mmol/L), phosphorus (mmol/L), proteinemia (g/L), Vitamin D (nmol/L), 1-25 OH vitamin D (pmol/L), PTH (ng/L), alkaline bone phosphatases (U/L), CTX (pg/ml)crosslaps, osteocalcin (µg/L), NFS, ferritin (µg/L), blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L), calciuria (mmol/L), urinary creatinin (mmol/L).

    Measured: Month 0 and Month 12

  33. ration lean mass / fat mass

    Dual-energy X-ray absorptiometry (DXA)

    Measured: Month 0

  34. ration lean mass / fat mass

    Dual-energy X-ray absorptiometry (DXA)

    Measured: Month 12

  35. Respiratory Functional Exploration

    Measured: Month 0

  36. Respiratory Functional Exploration

    Measured: Month 12

  37. Thickness intima / media

    echography

    Measured: Month 0

  38. Parameters of the connected watch : number of steps

    data recovery of the connected watch

    Measured: Month 0 and Month 6 and Month 12

  39. Parameters of the connected watch : distance traveled

    data recovery of the connected watch

    Measured: Month 0 and Month 6 and Month 12

  40. Parameters of the connected watch : calories consumption

    data recovery of the connected watch

    Measured: Month 0 and Month 6 and Month 12

  41. Ratio thickness intima / media

    echography

    Measured: Month 12

  42. Bone mineral density

    Dual-energy X-ray absorptiometry (DXA)

    Measured: Month 0

  43. Bone mineral density

    Dual-energy X-ray absorptiometry (DXA)

    Measured: Month 12

  44. Number of new fractures

    Measured: Month 1

  45. Number of new fractures

    Measured: Month 3

  46. Number of new fractures

    Measured: Month 6

  47. Number of new fractures

    Measured: Month 9

  48. Number of new fractures

    Measured: Month 12

  49. Quality of life questionnaire : PedsQL

    Measurement Model for the Pedratric Quality of Life Inventory

    The 4 Multidimensional Scales and 3 Summary Scores are

    Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)

    Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)

    Measured: Month 0

  50. Quality of life questionnaire : PedsQL

    Measurement Model for the Pedratric Quality of Life Inventory

    The 4 Multidimensional Scales and 3 Summary Scores are

    Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)

    Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)

    Measured: Month 6

  51. Quality of life questionnaire : PedsQL

    Measurement Model for the Pedratric Quality of Life Inventory

    The 4 Multidimensional Scales and 3 Summary Scores are

    Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)

    Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)

    Measured: Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2019
  2. Study start4 Nov 2019
  3. Primary completion14 Oct 2022
  4. Study completion14 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04119388
Sponsor's protocol ID
69HCL18_0747
Other IDs
ID-RCB
Acronym
MOVE-OI
Status last verified
Sep 2025
First submitted
1 Oct 2019
Last updated
10 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Al Arab H, Flammier S, Espitalier M, Bacchetta J, Fouillet-Desjonqueres M. Evaluation of the benefits of adapted physical activity in children and adolescents with osteogenesis imperfecta: the MOVE-OI trial. Orphanet J Rare Dis. 2025 Apr 12;20(1):175. doi: 10.1186/s13023-025-03678-4.

    PubMed 40221747

Questions about this trial

What is this clinical trial studying?

A study testing Adapted sports practices in people with Osteogenesis Imperfecta, run by Hospices Civils de Lyon at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

6 minutes walk test (time frame: Month 0). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04119388, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in